Medical Oncology

Prof. Dr. Nilüfer Avcı

Doctor and researcher Medicana Bursa Bursa
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medicana.com.tr.

  • Kanser çeşitleri; Meme, Akciğer, Mide, Pankreas, Sarkomlar, Prostat, Mesane, Kolorektal
  • Hedefli tedaviler
  • Kanserli hastada ağrı ve beslenme tedavisi
  • Beyin tümörleri

CV

Education and experience

From source

Experience

  • 1998-2002Kocaeli Üniversitesi Tıp Fakültesi İç Hastalıkları Ar.Gör.medicana.com.tr
  • 2002-2008Kocaeli Devlet Hastanesi Uzm. Dr. (İç Hastalıkları)medicana.com.tr
  • 2008-2012Uludağ Üniversitesi Tıp Fakültesi Tıbbi Onkoloji BD Yan Dal Asistanımedicana.com.tr
  • 2012-2014Balıkesir Devlet Hastanesi Uzm. Dr. (Tıbbi Onkoloji)medicana.com.tr
  • 2014-2016Ali Osman Sönmez Onkoloji Hastanesi Uzm. Dr. (Tıbbi Onkoloji)medicana.com.tr
  • 2016-2017Balıkesir Üniversitesi İç Hastalıkları / Medikal Onkoloji Doç. Dr. Nilüfer Avcımedicana.com.tr
  • 2017-2018Medikal Park Bursa Tıbbi Onkoloji Doç. Dr. Nilüfer Avcımedicana.com.tr
  • 2018-HalenMedicana Bursa Tıbbi Onkoloji Doç. Dr. Nilüfer Avcımedicana.com.tr

Education

  • 1990-1996Lisans Tıp Fakültesi Cumhuriyet Üniversitesimedicana.com.tr
  • 1990-1996Y. Lisans Tıp Fakültesi Cumhuriyet Üniversitesimedicana.com.tr
  • 1998-2002Doktora/S.Yeterlik/Tıpta Uzmanlık İç Hastalıkları Kocaeli Üniversitesimedicana.com.tr
  • 2008-2012Yan Dal (Tıbbi Onkoloji) Tıbbi Onkoloji Uludağ Üniversitesimedicana.com.tr
  • EducationDoçentlik Ünvanı Tıbbi Onkoloji, 04.04.2016medicana.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologymedicana.com.trFrom source
  • Department name at the sourceMedikal Onkolojimedicana.com.trFrom source
  • InstitutionMedicana Bursamedicana.com.trFrom source
  • Publications38 publicationsmedicana.com.tr profile pageFrom source
  • Last synchronised7 November 2026 03:21https://www.medicana.com.tr/hekim-detay/7696/nilufer-avcimedicana.com.tr

Scientific work

Publications

38 publications

  1. A1. Avci N, Cecener G, Deligonul A, Erturk E, Tunca B, Egeli U, Tezcan G, Akyildiz EU, Bayram AS, Gebitekin C, Kurt E, Evrensel T. Molecular markers for patients with thymic malignancies: not feasible at present? Asian Pac J Cancer Prev. 2014;15(8):3457-60. PubMed PMID: 24870739.

    Source: medicana.com.tr profile page

  2. A2. Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival. Asian Pac J Cancer Prev. 2015;16(4):1643-9. PubMed PMID: 25743846.

    Source: medicana.com.tr profile page

  3. A3. Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, Olmez F. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori. 2013 Mar-Apr;99(2):229-33. doi: 10.1700/1283.14197. PubMed PMID: 23748819.

    Source: medicana.com.tr profile page

  4. A4. Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015 Jan-Mar;20(1):45-9. PubMed PMID: 25778295.

    Source: medicana.com.tr profile page

  5. A5. Avci N, Deligonul A, Tolunay S, Cubukcu E, Olmez OF, Altmısdortoglu O, Tanrıverdi O, Kurt E, Evrensel T. Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy. J BUON. 2015 Jul-Aug;20(4):994-1000.

    Source: medicana.com.tr profile page

  6. A6. Cubukcu E, Olmez OF, Avci N, Canhoroz M, Kurt E, Kanat O, Evrensel T, Manavoglu O. Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors. J BUON. 2012 Jul-Sep;17(3):517-21. PubMed PMID: 23033292.

    Source: medicana.com.tr profile page

  7. A7. Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B, Alkis N. A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 2014 Dec 4;9(12):e114471. doi: 10.1371/journal.pone.0114471. PubMed PMID: 25474743; PMCID: PMC4256446.

    Source: medicana.com.tr profile page

  8. A8. Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, Cubukcu E, Coskun HS, Degirmenci M, Utkan G, Ozdemir N, Isikdogan A, Buyukcelik A, Inanc M, Bilici A, Odabasi H, Cihan S, Avci N, Yalcin B. Medication Errors in Chemotherapy Preparation and Administration: a Survey Conducted among Oncology Nurses in Turkey. Asian Pac J Cancer Prev. 2015;16(5):1699-705. PubMed PMID: 25773812.

    Source: medicana.com.tr profile page

  9. A9. Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, Sen CA, Avci N, Akman T, Ordu C, Goksel G, Meydan N. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy. Med Oncol. 2014 Oct;31(10):217. doi: 10.1007/s12032-014-0217-z. PubMed PMID: 25216865.

    Source: medicana.com.tr profile page

  10. A10. Tanriverdi O, Yildirim B, Gul S, Cevik E, Akman T, Cokmert S, Pilanci KN, Avci N, Ordu C, Barutca S. Effect of lower extremity deep vein thrombosis on cancer recurrence in stage III colon cancer patients. Med Oncol. 2014 Oct;31(10):215. doi: 10.1007/s12032-014-0215-1. PubMed PMID: 25208817.

    Source: medicana.com.tr profile page

View all 38 publications